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Abstract 29 
 30 
Antimicrobial resistance has been recognized by the World Health Organization (WHO) as one of the top three 31 
threats to human health. Any use of antibiotics in animals will ultimately also affect humans, and vice-versa. The 32 
importance of the appropriate monitoring of its usage and resistance has been repeatedly emphasized, as well as 33 
the need for global policies in this respect. Under the auspices of the EU research project EFFORT, the mapping of 34 
antimicrobial usage and resistance monitoring programs in ten European countries was performed, with a critical 35 
comparison with international and European guidelines/policies. Regarding the monitoring of resistance, we did 36 
not find important differences between countries. However, the current resistance monitoring systems are 37 
focused on food animal species (and fecal samples), ignoring, for example, companion animals.  The scenario is 38 
different considering the monitoring of antibiotics use. In the recent years, there has been a significant effort to 39 
harmonize methodologies. Despite this, the reporting of antimicrobials use is still voluntary. A need for stronger 40 
policies was identified.  41 
 42 
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Text 54 
Introduction 55 
 56 
Antimicrobial resistance (AMR) is recognized as one of the major global public health threats, with 57 
different reports emphasizing its economic impact (1,2), and the return to a “pre-antibiotics” era (3). It is 58 
a perfect example of a “one health” issue, as any use of antibiotics in animals will ultimately affect 59 
humans (and vice-versa)(4–6), with an associated environmental component (7–9), that recognizes no 60 
national boundaries (10). The development of resistance to antimicrobial drugs is a natural 61 
phenomenon, but the overuse and inappropriate use of these drugs, is associated with increased 62 
resistance. Therefore, the appropriate monitoring of the use of and development of resistance to these 63 
drugs are essential, if one is to achieve control of this problem. 64 
The World Health Organization (WHO) has recently recognized that there are significant gaps in 65 
(monitoring/surveillance) methods and no global consensus on standards for data collection and 66 
reporting of AMR across medical, veterinary and agricultural sectors (WHO, 2014). It is generally 67 
accepted that the comparison of results between countries is only possible when the results were 68 
obtained using the same (or similar/equivalent) procedures. 69 
Under the activities of the “Ecology from Farm to Fork Of microbial drug Resistance and Transmission” 70 
(EFFORT) EU-FP7 project, we conducted the mapping of the current monitoring activities related to 71 
antimicrobial use and resistance, in the ten European countries participating on the project: Belgium, 72 
Bulgaria, Denmark, France, Germany, Italy, Netherlands, Poland, Spain and Switzerland. Here we 73 
present the results of this mapping activity, as well as a critical comparison between the mapping results 74 
and the current related international guidelines/policies, from a gap analysis perspective.  75 
 4 
Materials and methods 76 
 77 
Initially, we took a very practical approach, having in mind the question: If a (European) country wants 78 
to set up monitoring systems to control the use and development of resistance to antimicrobials in 79 
animals, to which guidelines and policies should the competent authorities be looking at? As a follow-80 
up, we then did a critical comparison with individual countries policies, from a gaps identification 81 
perspective. In a second step, we mapped what countries are currently doing to monitor antibiotic use 82 
and resistance and finally did a gap analysis. 83 
International policy framework 84 
 85 
The WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) provided a 86 
guidance document with key information for the design of programs of integrated surveillance of 87 
antimicrobial (use) and resistance. Despite not being legally binding to countries, it does provide a 88 
generic overview of what countries need and show how to achieve the mentioned goals.  89 
European policy framework on monitoring of resistance in animals 90 
On a more specific EU level, Directive 2003/99/EC set out the goals on the monitoring of zoonoses and 91 
zoonotic agents and related antimicrobial resistance. By definition, as a “Directive”, it left up to the 92 
countries to decide how to achieve these goals; This was followed in 2007, by the publication of Decision 93 
2007/407/EC (by definition, a “Decision” is a binding legislative act on those to whom it is addressed, 94 
being directly applicable) specifically focusing on the harmonized monitoring of AMR in Salmonella in 95 
poultry and pigs. The most relevant and current related policy is probably Decision 2013/652/EU. It has a 96 
broader scope, addressing the monitoring and reporting of AMR in zoonotic and commensal bacteria 97 
(including Salmonella spp., Campylobacter jejuni (C. jejuni) and Campylobacter coli (C. coli), indicator 98 
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commensal Escherichia coli (E. coli), commensal Enterococcus faecalis and Enterococcus faecium (E. 99 
faecalis and E. faecium) and Salmonella spp. and E. coli producing Extended-Spectrum β-Lactamases 100 
(ESBL), AmpC  β-Lactamases (AmpC) and Carbapenemases). Technical specifications on randomized 101 
sampling for harmonized monitoring of AMR in these bacteria have been provided by EFSA (12).  102 
Global and European policy framework on monitoring of use in animals 103 
At the global level, OIE (Office International des Epizooties) provides guidelines on how to perform the 104 
monitoring of the quantities and use patterns of antimicrobial agents in aquatic animals, in its chapter 105 
6.3 of the Aquatic Animal Health Code; the equivalent for food-producing animals in provided in chapter 106 
6.8 of the Terrestrial Animal Health Code.  107 
Coordinated by the European Medicines Agency (EMA), the European Surveillance of Veterinary 108 
Antimicrobial Consumption (ESVAC) project was launched in September 2009, following a request to 109 
develop an approach for the harmonized collection and reporting of data on the use of antimicrobial 110 
agents in animals in the Member States (SANCO/E2/KDS/rzD(2008)520915). ESVAC provides data 111 
collection, reporting and analysis protocols, that can be followed by countries (13).  112 
Mapping exercise 113 
 114 
Initially, we mapped monitoring activities related to antimicrobial use and resistance including animals 115 
and food in countries participating in EFFORT in place in 2014. For this, we used a surveillance mapping 116 
methodology developed as part of another FP7 project (RISKSUR www.fp7-risksur.eu). After an initial 117 
online training, data collectors received a MS Word template to be completed with information 118 
regarding use of antimicrobials in their country, including: method to collect use data, animal 119 
populations known (size), indicator of use used, availability (or not) of Defined Daily Dose Animals 120 
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(DDDAs - also known as DDDvet in ESAVC project), the assumed average maintenance dose per day per 121 
kg body weight for the main indication in a specified species), classes of antimicrobials for which data 122 
was collected, specifications about the inclusion (or not) of premixes data, question about the potential 123 
existence of specific policies to discourage or alert about the overconsumption of antimicrobials and if 124 
veterinarians were allowed to sell antimicrobials or not. A similar procedure was used to collect the 125 
information about the monitoring of resistance, but via an MS Access database template. This database 126 
was completed with information about each monitoring activity/component like: the geographical focus 127 
of it, legal framework, target species and sectors, sampling points and samples collected, 128 
microorganisms tested, means of data acquisition, resistance criteria and whether the monitoring 129 
activity was funded and performed by the public or private sector.   130 
Results 131 
Resistance 132 
 133 
No major differences were found in the way the monitoring of resistance is being performed in the 134 
analysed European countries (Table 1). Testing resistance in microorganisms like Campylobacter jejuni, 135 
Campylobacter coli, E. coli and Salmonella spp. is being done in all the countries. In addition, few 136 
countries (ex. France) have national programmes for veterinary pathogens.  The focus of the monitoring 137 
programs is in the major food producing species (poultry, cattle and pigs). Slaughterhouses are the most 138 
common sample collection points, and the vast majority of the collected samples consist of faecal 139 
material. The monitoring activities are mostly active, and under the control of the public sector.  140 
 141 
 142 
 143 
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Table 1: Summary of the activities to monitor antimicrobial resistance, in animals, as of 2014, in the EFFORT participating countries. 145 
 
Microorganisms tested Animals species tested 
Collection of 
samples 
Samples collected 
Means of 
data 
acquisition 
Antimicrobial 
susceptibility 
test 
Resistance criteria 
Public 
vs 
Private 
Belgium Campylobacter coli ; Campylobacter jejuni ; 
Salmonella ; E. col ; Enterococci 
Poultry (broilers, laying hens and 
turkey) ; Pigs (finishers) ; Cattle (beef, 
dairy, veals) 
Abattoir Caecal; Faecal; 
Carcasses, meat and 
meat products (for 
poultry) 
Active and 
passive 
Dilution method 
and Diffusion 
method  
Clinical break-point 
and Epidemiological 
cut-off value  
All 
public 
Bulgaria Campylobacter coli; Campylobacter jejuni; 
Carbapenemase; E. coli; ESBL producers; Salmonella, 
Staphylococcus spp. 
Poultry (broilers, laying hens ); Pigs 
(finishers) ; Cattle (beef, dairy, veals); 
Sheep 
Abattoir Feces Active Diffusion 
method 
Clinical break-point Public 
Denmark Campylobacter coli; Campylobacter jejuni;E. coli; 
Enterococci; Salmonella spp.; Staphylococcus spp. 
Poultry (broilers); Pigs (sows/boars, 
finishers); Cattle (beef); other 
Abattoirs; Farms; 
Retailers; breeding 
herds 
Caecal; Blood; Cloacal; 
Rectum; Meat (pork, 
beef and broiler) 
Active Dilution method Epidemiological cut-
off value 
Public 
France Campylobacter coli ; Campylobacter jejuni ; E. coli; 
Enterococci; Pasteurella spp.; Salmonella spp.; 
Staphylococcus spp.; Streptococcus spp. 
Birds (non-poultry); Cats; Cattle 
(beef, dairy, veals), Dogs, Donkeys, 
Ducks, Fish, Goats, Horses, Pigs 
(suckling piglets, weaners, 
sows/boars, finishers); Poultry 
(broilers, laying hens); Rabbits; 
Sheep; Turkey 
Abattoir, Veterinary 
clinics and farms 
Caecal; Environmental; 
Different samples sent to 
the laboratory for 
diagnosis 
Active and 
Enhanced 
passive 
Dilution method 
and Diffusion 
method 
Epidemiological cut-
off value; Veterinary 
breakpoint 
established by CA-
SFM vet 
Public 
and 
Private 
Germany Campylobacter coli ; Campylobacter jejuni ; E. coli; 
Salmonella spp.; Methicillin-resistant Staphylococcus 
spp. (MRSA);  
In addition several animal pathogens (passive system) 
Poultry (broilers, laying hens and 
turkey) ; Pigs (sows/boars, finishers) ; 
Cattle (beef, dairy, veals) 
Abattoirs; Farms; 
Retailers; 
Caecal; Environmental; 
Meat (pork, beef, broiler 
and turkey meat); 
isolates from clinical 
samples sent for testing 
Active and 
Passive 
Dilution method Epidemiological cut-
off value; 
Public 
Italy Campylobacter coli; Campylobacter jejuni; 
Carbapenemase; E. coli; ESBL producers; Salmonella 
spp.; AmpC producers 
Poultry (broilers, laying hens and 
turkeys); Cattle (beef); Pigs (finishers) 
Farms; Abattoirs; 
Various points of 
the food chain 
Faeces; Environmental; 
Dairy products; Meat; 
Swabs from carcasses 
Active and 
Passive 
Dilution method Epidemiological cut-
off value  
Public 
Netherlands Campylobacter jejuni; Salmonella spp.; Enterococci; 
AmpC producers; Carbapenemase producers; E. coli; 
ESBL producers; MRSA; Pasteurella spp; 
Staphylococcus spp.; Streptococcus spp.; Listeria spp.; 
Mannheimia haemolytica; Histophilus somni; 
Klebsiella; Enterobacter; Actinobacillus 
pleuropneumoniae; Bordetella bronchiseptica; 
Haemophilus parasuis 
Poultry (broilers, laying hens, 
turkeys); Cattle (dairy, veals); Pigs 
(suckling piglets, weaners, 
sows/boars, finishers); Horses; 
Sheep; Goat 
Farms; Abattoirs; 
Veterinary clinics.  
Faeces; Clinical samples Active and 
Passive  
Dilution method 
and Diffusion 
method; Other 
Epidemiological cut-
off value;  
Clinical break-point; 
Other 
Public 
and 
Private  
Poland E. coli; Salmonella spp.; Staphylococcus spp.; 
Streptococcus spp.; MRSA; Pasteurella; mastitis agents 
Poultry (broilers, laying hens and 
turkeys) ; Cattle (beef and dairy) ; 
Pigs (suckling piglets, weaners, 
sows/boars, finishers) 
Farms; Abattoirs Rectal swabs; Cloacal 
swabs; Environment 
(boot swabs, dust, 
faeces); Diagnostic 
specimens (milk, faeces, 
organs, lesions)  
Active,  
Enhanced 
passive and 
Passive 
Dilution method 
and Diffusion 
method  
Epidemiological cut-
off value; Clinical 
break points 
Public 
Spain Campylobacter spp.; Enterococcus spp.; E. coli; 
Salmonella 
Cattle ; Gallus gallus (fowls) ; 
Broilers ; Laying hens ; Pigs 
(fattening) ;   
All food chain; 
slaughterhouses. 
Faeces; Lymph nodes Active Dilution method EUCAST CLSI Public 
Switzerland Campylobacter coli; Campylobacter jejuni; Enterococci; 
Carbapenemase; E. coli; ESBL producers; Salmonella 
spp.; AmpC producers; MRSA 
Poultry (broilers); Cattle (veals); Pigs 
(finishers) 
Abattoirs Rectal swabs; Cloacal 
swabs; Nasal swabs; 
Diverse (evaluation of 
resistance in Salmonella) 
Active and 
Passive  
Dilution method Epidemiological cut-
off value 
Public  
146 
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Use 147 
 148 
Table 2 summarizes the monitoring activities regarding the use of antimicrobials in the ten countries.  149 
Sales data (from pharmacies, feed companies, wholesalers and/or pharmaceutical companies) is the 150 
main source to derive/extrapolate use/consumption when such data is not available at national level. 151 
Besides this, automated data collection is in place in Denmark and The Netherlands, in combination with 152 
veterinary prescriptions data. In France, information is also collected via a retrospective longitudinal 153 
study.    154 
The antimicrobial use data is not divided by species in Belgium, Bulgaria and Italy. In the other countries 155 
included in this study, it is not always possible to disaggregate the consumption in the individual species 156 
(eg. dogs and cats are reported together in Denmark and France) and there is no common way of 157 
grouping the different animal species (eg. “cattle” is reported in a single category (dairy+beef) in 158 
Denmark, France and Poland while in the Netherlands usage data for rosé and white veal calves are 159 
reported separately from other cattle (dairy+beef)). 160 
In none of the countries are the size of all the animal population species (live and slaughtered, when 161 
applicable), known. 162 
“Total weight of Active Substance” is the indicator of usage reported in seven countries: Belgium, 163 
Bulgaria, Denmark, France, Germany, and The Netherlands. In Belgium and France, “Weight of Active 164 
Substance per biomass at risk to be treated” (units: mg AS/PCU) is also used, and this is the only 165 
indicator used in Italy, Poland, Spain and Switzerland. Additionally, France uses the Animal Level of 166 
Exposure to Antimicrobials (ALEA, the DCDA divided by the biomass) and the Netherlands the “Number 167 
of days treated per individual” (Total amount of Kg, irrespective of active ingredient, by Kg of active 168 
substance/year, by pharmaco-therapeutic group (DDDA nat and DDDAfarm/year)). 169 
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A list of DDDA`s is not available in Bulgaria, Germany, Italy, Poland, Spain and Switzerland. Belgium has 170 
established it (for pigs and poultry) by product, active substance, administration route and age group; 171 
Denmark by product, administration route and age group, France by product and The Netherlands by 172 
active substance and ATCvet category.  173 
All the countries have data collected and available for all the antimicrobial classes (according with the 174 
ATCvet index list). Premixes data are included in the usage data in all the countries, except in Germany 175 
and The Netherlands. 176 
Denmark, Germany and The Netherlands have in place specific policies to discourage, or alert to the 177 
“overconsumption” of antimicrobials, in opposition to the other seven countries.  178 
Veterinarians are allowed to sell antimicrobials in Belgium, France, Germany, Poland, The Netherlands 179 
and Switzerland. 180 
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 181 
Table 2: Summary of the activities to monitor antimicrobial use, in animals, as of 2014, in the EFFORT participating countries. 182 
 
Data collection Consumption separated by species An. pop. unknown 
(l=live; s=slaughtered) 
Indicator of usage DDDAs available? 
AM 
classes 
collected 
Premixes  
included 
“Yellow 
card”? 
Vets 
sell? 
Belgium Sales (feed companies and 
wholesalers) 
No Cats (l); Dogs (l); Ducks (s); Fish (l&s); Goats (s); 
Horses (s); Pigs: suckling piglets (l&s), weaners (s), 
sows/boars (s); Poultry: laying hens (s); Rabbits (s); 
Sheep (s); Turkey (s) 
Total weight of AS; 
Weight of AS per 
biomass at risk to 
be treated  
Yes (by product, 
AS, administration 
route, age group, 
for pigs and 
poultry) 
all Yes No Yes 
Bulgaria Sales ( wholesalers and 
pharmaceutical companies) 
No Cats (l); Dogs (l); Birds (non-poultry) (l&s); Ducks 
(l&s); Fish (l&s); Rabbits (l&s); Turkey (l&s) 
Total weight of AS  
 
No all Yes No No 
Denmark Automated data collection; 
Sales (pharmacies and feed 
companies); veterinary 
prescriptions 
Yes: dogs+cats (pharmacy data); cattle 
(dairy+beef); fish; goats; pigs 
(weaners, sows/boars, finishers); 
poultry (broilers, laying hens), sheep, 
turkey; horses (pharmacy data) 
Birds (non-poultry) (l&s); Cats (l); Dogs (l); Donkeys 
(l); Fish (l); Horses (l&s); Pigs: suckling piglets (s), 
weaners (s), sows/boars (s); Poultry: laying hens 
(s); Rabbits (l&s); Sheep (l&s); Turkey (l&s) 
Total weight of AS  
 
Yes (by product, 
administration 
route, age group) 
all Yes Yes No 
France Retrospective longitudinal 
study; Sales 
(pharmaceutical 
companies) 
Yes:Dogs+cats; Cattle; fish; horses; 
Pigs; poultry (including turkeys and 
ducks); rabbits; sheep+goats 
Birds (non-poultry) (l); Cattle: beef (s), dairy (s), 
veals (l); Ducks (l); Fish (l); Horses (s); Pigs: suckling 
piglets (l&s), weaners (l); finishers (l); Poultry: 
broilers(l), laying hens (l); Rabbits (l); Turkey (l) 
Total weight of AS; 
Weight of AS per 
biomass at risk to 
be treated ; ALEA 
Yes (by product) all, except 
QJ01R  
Yes No Yes 
Germany Sales (pharmaceutical 
companies) 
Yes:Pigs (weaners, finishers); poultry 
(broilers); turkey 
Birds (non-poultry) (l&s); Donkeys (l); Fish (l&s); 
Goats (l&s); Pigs: suckling piglets (l&s); Rabbits 
(l&s); Sheep (l&s) 
Total weight of AS 
 
No all No No Yes 
Italy Sales (pharmaceutical 
companies) 
No Cats (l) Weight of AS per 
biomass at risk to 
be treated  
 
No all Yes No No 
Netherlands Automated data collection; 
Sales (pharmaceutical 
companies); Veterinary 
prescriptions 
Yes: cattle; pigs; poultry (broilers); 
turkey 
Birds (non-poultry) (l&s); Ducks (l&s); Fish (l&s); 
Rabbits (s) 
Total weight of AS; 
Number of days 
treated per 
individual 
(DDDAnat and 
DDDAfarm) 
Yes (by AS, ATC vet 
category) 
all  No Yes Yes 
Poland Sales (wholesalers) Yes: cattle; goats; pigs; poultry; sheep Cats (l); Dogs (l); Birds (non-poultry) (l&s); Ducks 
(l&s); Fish (l&s); Rabbits (l&s); Turkey (l&s) 
Weight of AS per 
biomass at risk to 
be treated  
No all, except 
QJ01R 
Yes No Yes 
Spain Sales (pharmaceutical 
companies) 
Yes: birds (non-poultry); cats; dogs; 
fish; goats; horses; fish, salmon, trout; 
cattle; poultry; pigs 
Cats (l); Dogs (l); Birds (non-poultry) (l&s); Ducks 
(l&s); Fish (l&s); Rabbits (l&s); Turkey (l&s) 
Weight of AS per 
biomass at risk to 
be treated 
No all, except 
QJ01R and 
QJo1X 
Yes No No 
Switzerland Sales (pharmaceutical 
companies) 
No. Birds (non-poultry) (l&s); Cats (l); Cattle: beef (l), 
veals (l); Dogs (l); Donkeys (l); Ducks (l&s); Fish 
(l&s); Goats (l); Pigs: suckling piglets (l&s), weaners 
(l&s), sows/boars (s), finishers (l); Poultry: broilers 
(l), laying hens (l); Rabbits (l); Turkey (l&s) 
Weight of AS per 
biomass at risk to 
be treated 
No all Yes No Yes 
183 
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Discussion 184 
 185 
The EC Decision 652/2013 on the monitoring and reporting of antimicrobial resistance in 186 
zoonotic and commensal bacteria, is binding on all the EU countries (14). Considering this, it 187 
was not surprising that few differences were found on the way countries are monitoring the 188 
level of resistance. However, there are several aspects that this policy does not cover, that 189 
should be addressed in upcoming policies. The current monitoring activities are mostly 190 
focused on food producing animals. But, for example, fish (aquaculture) are not considered 191 
(being aware that this is not a developed sector in all the EU countries). Considering some 192 
recent reports (15), particular attention should be given to this section, in the near future. 193 
The mandatory monitoring is mostly performed via faecal material. While most of the 194 
prudent use guidelines in veterinary medicine recommend a good diagnosis, antibiogramme 195 
use  and epidemiological knowledge of animal disease, no strong regulations have been 196 
established to support the best practice in veterinary laboratories. This way, resistance 197 
developing microorganisms that live in different body organs (lungs, mammary gland, 198 
uterus, etc.) might be missed. The direct sampling and analysis of food samples is also not 199 
mandatory. Including these analyses in the routine European mandatory activities would be 200 
labour and financially demanding, and cross-contamination issues would have to be carefully 201 
taken into account. In any case, it would certainly help to clarify, and above all to quantify, 202 
the different transmission AMR pathways between humans and animals, areas that despite 203 
progress in the past few years, still have significant knowledge gaps. Metals exposure (like 204 
silver and zinc oxide) has been recognized as a factor contributing to AMR selection (16,17), 205 
but the current policies do not mandate the monitoring of resistance to these agents. 206 
Antimicrobial resistant bacteria have been repeatedly identified in “environmental” samples 207 
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(7–9), but despite this, the monitoring of resistance via “environmental” samples is currently 208 
not mandatory. Having this information would be quite useful to better understand the 209 
spread of resistance between humans, animals and the environment. 210 
The vast majority of the current monitoring activities are “active” (vs passive collection of 211 
information) and manage and funded by the public authorities of each country. Considering 212 
that antimicrobials are a public good, these approaches make sense, and facilitate both the 213 
harmonization and transparency of methods. On the other hand, it is the private 214 
industry/owners that mostly make the use of antimicrobials, thereby benefiting from them. 215 
It is also true that they are the ones directly affected with all the adverse consequences 216 
(both in humans and animals) of the existence of resistance. Therefore, an increased 217 
involvement of the private industry would be desirable.  218 
The scenario is significantly different regarding the monitoring of the use of antimicrobials. 219 
This can perhaps be mostly explained by the fact that there is currently not any binding 220 
European policy that mandates countries to report their use of antimicrobials in the animal 221 
sector, with specific guidelines. The legal framework for veterinary medicinal products 222 
currently under revision can be an opportunity to change this policy reality, and it does seem 223 
that at least report sales quantities will become mandatory, with mandatory monitoring to 224 
be implemented in two to three years.  225 
The ESVAC project has been certainly contributing for the collection of harmonized data. 226 
However, most of the data collected still refers to sales data, and not use data. This scenario 227 
is planned to change in a relatively near future(18).  Collecting the actual use data at the 228 
farm level, is certainly a demanding task for different agents involved in this sector, but it is, 229 
at the same time, the most accurate way. An antibiotic sold, is not an antibiotic used, and 230 
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only the recording of the actual use will avoid the need for approximations, corrections and 231 
use of other indicators of use.  232 
 Knowing the animal population at risk, i.e., the denominator regarding the use of the 233 
antimicrobials, is critical. In the analyzed countries, the major food producing animal 234 
populations are known (poultry, cattle and pigs), but this is not always true for other “minor” 235 
species. The use/sales of antimicrobials is reported in such a way that does not always allow 236 
the differentiation between the different species, types and stages of production, and this is 237 
critical when it comes to identifying the species and stages of the food chain where 238 
prevention and control measures should focus on. Currently, the same antibiotic commercial 239 
product can be commercialized/is indicated for different animal species, creating an 240 
additional hurdle when it comes to the quantification of its use in a specific species.   241 
The usefulness of having a “yellow card” policy has been recognized in Denmark (19). Under 242 
this policy, a farmer receives a yellow card if he/she uses antimicrobials in a quantity two 243 
times higher than the national average. However, such policies only exist in Denmark and 244 
The Netherlands. The same way, the implementation of policies that restrict the sales of 245 
antimicrobials by veterinarians have had positive impact (20), but at the moment such 246 
policies only exist in half of the analyzed countries. 247 
Conclusion 248 
 249 
The current European policies regarding the monitoring of resistance in animals, provide 250 
specific guidelines when it comes to food producing animals. However, most of the analyses 251 
to be performed are based on faecal samples, and, for example, companion animals, food 252 
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and the environment are not even considered. Important gaps that we here suggest to be 253 
addressed in upcoming policies.  254 
At the moment, there is not an European policy that mandates countries to report their use 255 
of antimicrobials in animals, and most of the data available is based on sales, and not use 256 
data.  257 
Considering the unanimously recognized significant dimension of the AMR problem, these 258 
scenarios should be urgently changed. The EU ban on the usage of growth promoters in 259 
2006 provided a strong global message, and the EU is recognized as an AMR best practices 260 
region (Plantady, 2016, personal communication). Developing and implementing the policies 261 
suggested in this paper, should inform policy development in other regions where similar 262 
activities may still be lacking.   263 
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